Allspring Global Investments Holdings LLC Has $683,000 Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Allspring Global Investments Holdings LLC boosted its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 6.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 87,155 shares of the medical instruments supplier’s stock after buying an additional 5,295 shares during the period. Allspring Global Investments Holdings LLC’s holdings in AngioDynamics were worth $683,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. SG Capital Management LLC bought a new stake in shares of AngioDynamics during the third quarter worth about $561,000. Acadian Asset Management LLC purchased a new position in AngioDynamics during the 3rd quarter worth $2,630,000. Trexquant Investment LP bought a new stake in shares of AngioDynamics in the 3rd quarter worth $1,373,000. Jacobs Levy Equity Management Inc. raised its holdings in shares of AngioDynamics by 62.4% in the third quarter. Jacobs Levy Equity Management Inc. now owns 713,899 shares of the medical instruments supplier’s stock valued at $5,219,000 after purchasing an additional 274,210 shares during the last quarter. Finally, Barclays PLC lifted its position in shares of AngioDynamics by 43.4% during the third quarter. Barclays PLC now owns 38,155 shares of the medical instruments supplier’s stock valued at $280,000 after purchasing an additional 11,556 shares in the last quarter. 89.43% of the stock is owned by institutional investors.

Insider Transactions at AngioDynamics

In other news, CEO James C. Clemmer acquired 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 8th. The shares were acquired at an average price of $6.70 per share, for a total transaction of $67,000.00. Following the completion of the purchase, the chief executive officer now owns 539,066 shares in the company, valued at $3,611,742.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 5.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on ANGO shares. Raymond James reduced their price objective on shares of AngioDynamics from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Tuesday, January 9th. Oppenheimer raised AngioDynamics from a “market perform” rating to an “outperform” rating and set a $12.00 price target for the company in a research report on Friday, April 5th. Finally, HC Wainwright cut their price objective on AngioDynamics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Monday, January 8th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $14.25.

AngioDynamics Stock Performance

Shares of ANGO stock opened at $5.87 on Thursday. The firm has a market cap of $235.15 million, a price-to-earnings ratio of -1.21 and a beta of 0.66. AngioDynamics, Inc. has a 52 week low of $5.26 and a 52 week high of $11.38. The firm’s 50-day simple moving average is $5.93 and its two-hundred day simple moving average is $6.42.

About AngioDynamics

AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.